化合物NT157 T4605

Product Introduction
Bioactivity


英文名: NT157

描述: NT157 是一种口服生物可利用的间充质-上皮转化 (MET) TKI，主要针对具有 METex14 跳跃突变的特定 NSCLC 患者开发。

体外活性: NT157 treatment resulted in dose-dependent inhibition of IGF1R activation, suppression of IRS protein expression, inhibition of IGF1-induced AKT activation, but increased ERK activation in NT157-treated cells in vitro[2].

体内活性: NT157 suppressed androgen-responsive growth, delayed CRPC progression of LNCaP xenografts, and suppressed PC3 tumor growth alone and in combination with docetaxel[2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 77 mg/ml(186.78 mM)
Ethanol : 25.83mg/ml(186.78 mM)


关键字: NT157 | NT-157 | NT 157

相关产品: ALK inhibitor 1 | Ganitumab | MID-1 | NBI-31772 | NVP-AEW541 | Dusigitumab | NVP-ADW742 | AGL-2263 | AZD-3463 | Picropodophyllotoxin

相关库: Anti-Prostate Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Anti-Lung Cancer Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Reprogramming Compound Library | Bioactive Compound Library

化合物NT157 T4605信息由TargetMol中国为您提供，如您想了解更多关于化合物NT157 T4605报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途